EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer - Wikidata - wikimedia - TriplyDB

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

http://www.wikidata.org/entity/Q33856378

about

Monoclonal antibodies for the treatment of cancer The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules.The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.

P2860

Q27025966-D295230F-56AA-4F4B-AEA9-D225D8F67793 Q34057608-CA160A02-A0EB-4810-83A8-F45BD9C79B70 Q34776118-6B0A7595-2283-41D8-A852-19C662E2B171 Q34998534-103F2977-6286-455C-B517-C23F3C42DEF5 Q36224208-58FBE40D-CA70-4B86-A477-B15B1F1E8AF3 Q37130603-B7066F20-01E2-45EB-B230-56C5F8290973 Q37636844-9324D821-94DF-4AD6-B778-B9AD8CB148BA

P2860

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

http://www.wikidata.org/entity/Q33856378

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

EGFR related mutational status ...... n metastatic colorectal cancer

@ast

EGFR related mutational status ...... n metastatic colorectal cancer

@en

type

label

EGFR related mutational status ...... n metastatic colorectal cancer

@ast

EGFR related mutational status ...... n metastatic colorectal cancer

@en

prefLabel

EGFR related mutational status ...... n metastatic colorectal cancer

@ast

EGFR related mutational status ...... n metastatic colorectal cancer

@en

P1433

Q33856378-5FA05FA8-5993-4E0C-AF3B-269DD352E490

P1476

Q33856378-CBB7CB42-FF11-4933-A9A3-152175B953BC

P2093

Q33856378-157BB142-B5CC-4007-9583-936AEEAE235D

Q33856378-186FF605-B6CD-4463-A6F3-49E53A0DC5EB

Q33856378-7465F767-095A-4325-B533-A41686BB07FE

Q33856378-B53A9CD8-D034-45E4-888D-483D1D94214E

Q33856378-B950BA83-67F8-474F-8A85-281E6F5AD9C4

P2860

Q33856378-02007AD3-113E-4830-BD83-157B31E0DDE0

Q33856378-0A508B9B-974C-497D-AC81-63BC54A07404

Q33856378-118E5EE2-CF9D-4B52-BC41-34D0CE2DC1DF

Q33856378-1D0879DB-8091-415B-91D2-3CA5F7E5CEC6

Q33856378-23DDE72C-4024-4E8C-BD68-17986F0FD34C

Q33856378-2C255FB7-5850-4F35-8A1A-04B501BCDBDF

Q33856378-3A86E954-953F-4E0D-AD60-F8D12AA15172

Q33856378-5DE7E1D0-5175-490F-B032-96B69FAB4900

Q33856378-633785FF-5EAA-4E70-8483-1EC426DB9B52

Q33856378-7300A43C-0A2F-40CC-BF23-CAC26266AE7A

P2888

Q33856378-13F1479A-3616-4EAF-959B-2D57969FB499

P304

Q33856378-3E373ED2-46E2-4D43-91CD-6994A8D93F8C

P31

Q33856378-9E944E28-4CD8-4119-801C-6E6513B43C55

P356

Q33856378-61996DEF-64C3-4E00-A0B1-A2E140DE9211

P407

Q33856378-0B257155-238A-4A1E-AD26-4AB3F0E48190

P478

Q33856378-624E892D-EBA8-454D-A7D7-925EEF85C238

P577

Q33856378-1B5118D0-2049-4764-B89E-20A1D988FA6A

P5875

Q33856378-A2E0FA1D-7051-48EC-A00B-5EF53935612F

P6179

Q33856378-BF5C3076-4A42-46AB-8163-3928B4BBD73E

P698

Q33856378-89C8AFE2-250D-4A95-B2C4-84E8694832B1

P921

Q33856378-72D564B1-8164-4AA5-82F3-1E4551F22662

Q33856378-CD692908-2EF9-43B3-9F14-E7E280A98881

P932

Q33856378-BA44AEAD-D2E8-4D00-B5D8-1456A6CC3559

P356

1471-2407-11-107

P1433

P1476

EGFR related mutational status ...... n metastatic colorectal cancer

@en

P2093

Anders Jakobsen

http://www.w3.org/2001/XMLSchema#string

Jan Lindebjerg

http://www.w3.org/2001/XMLSchema#string

Karen-Lise G Spindler

http://www.w3.org/2001/XMLSchema#string

Niels Pallisgaard

http://www.w3.org/2001/XMLSchema#string

Sanne K Frifeldt

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

P2888

1471-2407-11-107

P304

107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-107

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50865534

http://www.w3.org/2001/XMLSchema#string

P6179

1026865034

http://www.w3.org/2001/XMLSchema#string

P698

21439039

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3073939

http://www.w3.org/2001/XMLSchema#string